Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

Trial Details

NCT ID

NCT04956640

Phase

PHASE1 / PHASE2

Sponsor

Eli Lilly and Company

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

LY3537982
Pembrolizumab
Cetuximab
Pemetrexed
Cisplatin
Carboplatin

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Los Angeles, California, United States|34.05223,-118.24368
Orange, California, United States|33.78779,-117.85311
New Haven, Connecticut, United States|41.30815,-72.92816
Orlando, Florida, United States|28.53834,-81.37924

Key Eligibility Criteria

Patients have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).
Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and meet coho…
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →